Article

4 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 71, n° 6
page 1183 (décembre 2014)
Doi : 10.1016/j.jaad.2014.08.039
accepted : 21 August 2014
Original Articles

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
 

Kim Papp, MD, PhD a, , Craig Leonardi, MD b, Alan Menter, MD c, Elizabeth H.Z. Thompson, PhD d, Cassandra E. Milmont, PhD d, Greg Kricorian, MD d, Ajay Nirula, MD, PhD d, Paul Klekotka, MD, PhD d
a Probity Medical Research, Waterloo, Ontario, Canada 
b Saint Louis University, Saint Louis, Missouri 
c Baylor University Medical Center, Dallas, Texas 
d Amgen Inc, Thousand Oaks, California 

Correspondence to: Kim Papp, MD, PhD, Probity Medical Research, 135 Union St E, Waterloo, Ontario N2J 1C4 Canada.
Abstract
Background

Brodalumab (anti–interleukin-17-receptor antibody) was effective in treating moderate to severe psoriasis in a 12-week, dose-ranging, placebo-controlled trial.

Objective

We sought to evaluate efficacy and safety of long-term brodalumab treatment.

Methods

In this interim analysis at week 120 of an open-label extension study, patients received brodalumab 210 mg every 2 weeks. Protocol amendments reduced the dose (140 mg) in patients weighing 100 kg or less and subsequently increased the dose (210 mg) in patients with inadequate responses. Efficacy was measured by static physician global assessment and 75% or greater, 90% or greater, or 100% improvement in Psoriasis Area and Severity Index score (PASI-75, PASI-90, and PASI-100, respectively).

Results

Of 181 patients, 144 completed week 120. Static physician global assessment scores of clear/almost clear and clear were achieved by 90% and 63% of patients, respectively, at week 12 and by 72% and 51% at week 120. The PASI-75, PASI-90, and PASI-100 response rates at week 12 (95%/85%/63%) were sustained through week 120 (86%/70%/51%). Most commonly reported adverse events were nasopharyngitis (26.5%), upper respiratory tract infection (19.9%), arthralgia (16.0%), and back pain (11.0%). Four patients had grade-2 absolute neutrophil count.

Limitations

There was no control group in this open-label extension.

Conclusion

Brodalumab demonstrated sustained clinical response and an acceptable safety profile through 120 weeks in patients with moderate to severe psoriasis.

The full text of this article is available in PDF format.

Key words : anti–interleukin-17 therapy, brodalumab, clinical trial, efficacy, long-term treatment, open-label extension, psoriasis, safety

Abbreviations used : AE, DLQI, IL, OLE, PASI, PASI-75, PASI-90, PASI-100, Q2W, SF-36v2, sPGA



 Supported by Amgen Inc. Brodalumab is being co-developed by Amgen Inc and AstraZeneca/MedImmune.
 Disclosure: Dr Papp is a consultant, an investigator, and on the speakers bureau for AbbVie, Amgen, Astellas, Bayer, Boehringer Ingelheim, Celgene, Eli Lilly, Forward, Galderma, Janssen, LEO, Merck, Novartis, Pfizer, Roche, and UCB. Dr Leonardi has served as a consultant, an investigator, and/or speaker for Abbott, Amgen, Celgene, Centocor, Eli Lilly, Galderma, Genentech, Genzyme, GlaxoSmithKline, Incyte, Janssen Biotech, Maruho, Novartis, Novo Nordisk, Pfizer, Schering-Plough, Sirtris, Stiefel, Vascular Biogenics, and/or Wyeth. Dr Menter is on an advisory board for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, LEO, and Pfizer; is a consultant for AbbVie, Allergan, Amgen, Convoy Therapeutics, Eli Lilly, Janssen Biotech, LEO, Novartis, Pfizer, Syntrix Biosystems, Wyeth, and XenoPort; is an investigator for AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Eli Lilly, Genentech, Janssen Biotech, LEO, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix Biosystems, and Wyeth; and is on the speakers bureau for AbbVie, Amgen, Janssen Biotech, LEO, and Wyeth. Drs Milmont, Kricorian, Nirula, and Klekotka are employees and shareholders of Amgen. Dr Thompson is a former employee of Amgen and is a shareholder of Amgen.
 Supplemental tables are available at www.jaad.org.
 Reprints not available from the authors.



© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline